GENELUX Corp

GNLX

GENELUX Corp

GNLX

Insider Sentiment (TTM):

Last Purchase:2024-05-29Last Sale:2026-06-03Shares Purchased (TTM):0Shares Sold (TTM):46,724

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:9,268,229Shares Outstanding:44,150,958Institutional Ownership Pct.:20.99%

Earnings Market Reaction:

Filing Date:2026-08-13Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	9	9	5	-	7	16	9	6	8	4	9	30
Restricted Cash And Cash Equivalents At Carrying V…	-	9	-	5	-	-	-	-	-	-	-	-
Short Term Investments	-	17	-	16	21	19	22	28	26	16	14	-
Marketable Securities	9	17	9	-	-	-	22	-	-	-	-	-
Prepaid Expense And Other Assets Current	0	1	1	1	1	1	1	2	1	2	1	1
Assets Current	19	27	15	22	29	36	32	36	35	21	24	31
Property Plant And Equipment Net	5	3	2	2	1	1	1	1	1	1	1	1
Operating Lease Right Of Use Asset	2	2	2	2	2	2	2	2	2	2	2	2
Long Term Investments	-	-	-	-	-	-	-	1	7	-	-	-
Other Assets Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Assets Noncurrent	-	-	-	3	3	3	3	4	10	3	4	3
Assets	26	32	19	25	32	39	35	40	45	25	28	34
Liabilities And Stockhold…
Liabilities Current
Accounts Payable And Accrued Liabilities Current	7	6	4	4	6	7	6	4	5	5	4	4
Accrued Payroll Taxes Current	1	1	1	1	1	1	1	1	1	2	2	4
Operating Lease Liability Current	0	0	0	0	0	0	0	0	1	1	1	1
Liabilities Current	8	7	6	5	7	8	7	6	6	8	7	9
Operating Lease Liability Noncurrent	2	2	1	1	1	1	2	2	2	2	2	1
Liabilities	10	9	7	6	8	9	8	7	8	10	8	10
Stockholders Equity
Convertible Notes Payable Current	-	-	-	-	-	-	-	-	-	-	-	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Treasury Stock Value	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Additional Paid In Capital	318	316	295	293	291	289	278	276	274	245	241	239
Liabilities Noncurrent
Accumulated Other Comprehensive Income Loss Net Of…	-0	-0	0	0	0	0	0	0	-0	-0	0	0
Retained Earnings Accumulated Deficit	-302	-292	-284	-274	-266	-259	-251	-242	-236	-229	-222	-215
Stockholders Equity	16	23	12	19	24	30	26	33	38	15	19	24
Liabilities Noncurrent	-	-	-	-	-	-	-	-	-	-	2	1
Liabilities And Stockholders Equity	26	32	19	25	32	39	35	40	45	25	28	34
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	200	200	200	200	200	200	200	200	200	200	200	200
Preferred Stock Par Or Stated Value Per Share	-	-	0.001	-	-	0.001	0.001	0.001	0.001	0.001	0.001	-
Common Stock Shares Issued	45	45	38	-	38	38	35	35	35	27	27	27
Preferred Stock Shares Authorized	-	-	10	-	-	10	10	10	10	10	10	-
Preferred Stock Shares Issued	-	-	-	-	-	0	0	0	0	-	0	-
Preferred Stock Shares Outstanding	-	-	-	-	-	0	0	0	0	-	0	-
Shares Outstanding	45	45	38	38	38	38	35	35	35	27	27	27
Treasury Stock Common Shares	0	0	0	0	0	0	0	0	0	0	0	0

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	7.77%	1.41%	2.12%	-	-	-	-	-	-	-	-	-
2025	3.86%	28.33%	43.35%	-0.30%	25.75%	134.13%	-29.08%	-44.26%	-63.39%	0.00%	22.44%	15.35%
2024	-32.59%	-51.49%	-45.52%	33.97%	20.57%	53.59%	-7.82%	-13.61%	34.35%	-14.61%	-19.48%	-0.65%
2023	-	-	-	-0.66%	9.14%	-24.62%	-11.99%	-4.73%	-32.83%	-	-	-
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	2.39	3.68	2.43	4.20	4.18	4.67	4.57	6.47	6.01	2.72	3.69	3.56
Quick Ratio	2.33	3.60	2.34	4.08	4.00	4.57	4.48	6.13	5.80	2.51	3.54	3.41
Working Capital	11.15M	19.48M	8.91M	16.43M	22.25M	28.26M	24.65M	30.41M	29.07M	13.40M	17.65M	22.42M
Leverage & Debt
Debt to Equity	0.63	0.41	0.65	0.34	0.35	0.31	0.32	0.22	0.20	0.64	0.43	0.42
Interest Coverage TTM	-	-	-	-	-	-	-	-4,824.83	-157.89	-149.24	-139.68	-
Debt Ratio	0.39	0.29	0.39	0.26	0.26	0.23	0.24	0.18	0.17	0.39	0.30	0.29
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	-
Per Share Metrics
Diluted EPS TTM	-0.79	-0.76	-0.86	-0.84	-0.80	-0.84	-0.95	-0.80	-0.89	-0.96	-1.16	-
Free Cash Flow Per Share TTM	-0.60	-0.63	-0.71	-0.49	-0.46	-0.65	-0.69	-0.71	-0.75	-0.78	-0.87	-
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-
Margin Metrics
Operating Profit Margin TTM	-	-	-	-	-	-	-396,200.00%	-361,862.50%	-341,437.50%	-322,725.00%	-14,214.71%	-
Net Profit Margin TTM	-	-	-	-	-	-	-373,362.50%	-345,750.00%	-331,725.00%	-322,287.50%	-16,645.29%	-
Growth Metrics
Net Revenue Growth (1Y)	-	-	-100.00%	-100.00%	-100.00%	-100.00%	-95.29%	-	-	-	-	-
Net Income Growth (1Y)	17.13%	13.79%	7.62%	15.23%	14.52%	14.46%	5.56%	-	-	-	-	-
EPS Growth (1Y)	-1.14%	-9.98%	-8.96%	5.01%	-10.40%	-12.01%	-18.01%	-	-	-	-	-
Valuation Metrics
P/E TTM	-3.80	-3.18	-5.04	-4.99	-3.58	-3.20	-2.48	-2.96	-2.18	-6.70	-12.10	-
P/B TTM	8.40	4.66	14.04	8.56	4.56	3.16	2.82	2.47	1.54	11.45	17.58	26.71
P/S TTM	-	-	-	-	-	-	9,277.96	10,230.21	7,236.78	21,580.48	2,013.26	-
Market Cap	135.33M	106.85M	162.09M	159.15M	108.91M	94.30M	74.22M	81.84M	57.89M	172.64M	342.25M	641.88M
Enterprise Value	126.14M	97.57M	156.76M	154.46M	102.36M	78.09M	65.66M	75.74M	50.04M	168.58M	332.84M	612.06M
Calculated Values
Free Cash Flow TTM	-27.17M	-27.88M	-26.37M	-18.66M	-17.35M	-22.69M	-21.61M	-24.36M	-22.22M	-20.99M	-21.30M	-
Net Debt	-9.18M	-9.27M	-5.33M	-4.69M	-6.55M	-16.21M	-8.57M	-6.10M	-7.86M	-4.06M	-9.42M	-29.83M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-03Sale

Owner: Smalling, Ralph

Title: Head of Regulatory

Shares: 192

Price/Share: $2.93

Value: $562.56

Shares Owned: 67,611

Relationship: Officer

Ownership: Direct

2026-06-01Sale

Owner: Thomas, John

Title: -

Shares: 10,000

Price/Share: $2.98

Value: $29,800.00

Shares Owned: 472,784

Relationship: Director

Ownership: Direct

2026-05-11Sale

Owner: Zindrick, Thomas

Title: President and CEO

Shares: 2,798

Price/Share: $2.94

Value: $8,226.12

Shares Owned: 532,051

Relationship: Officer

Ownership: Direct

2026-05-11Sale

Owner: Yu, Yong

Title: Chief Scientific Officer

Shares: 605

Price/Share: $2.97

Value: $1,796.85

Shares Owned: 149,706

Relationship: Officer

Ownership: Direct

2026-05-11Sale

Owner: Smalling, Ralph

Title: Head of Regulatory

Shares: 270

Price/Share: $2.98

Value: $804.60

Shares Owned: 67,803

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-03	Smalling, Ralph	Officer	Head of Regulatory	Direct	Sale	192	2.93	$562.56	67,611	4
2026-06-01	Thomas, John	Director	-	Direct	Sale	10,000	2.98	$29,800.00	472,784	4
2026-05-11	Zindrick, Thomas	Officer	President and CEO	Direct	Sale	2,798	2.94	$8,226.12	532,051	4
2026-05-11	Yu, Yong	Officer	Chief Scientific Officer	Direct	Sale	605	2.97	$1,796.85	149,706	4
2026-05-11	Smalling, Ralph	Officer	Head of Regulatory	Direct	Sale	270	2.98	$804.60	67,803	4
2026-05-11	Cappello, Joseph	Officer	Chief Technical Officer	Direct	Sale	605	2.97	$1,796.85	154,549	4
2026-03-25	Smalling, Ralph	Officer	Head of Regulatory	Direct	Sale	240	2.51	$602.40	68,073	4
2026-03-24	Cappello, Joseph	Officer	Chief Technical Officer	Direct	Sale	906	2.42	$2,192.52	155,154	4
2026-03-24	Zindrick, Thomas	Officer	President and CEO	Direct	Sale	3,582	2.42	$8,668.44	534,849	4
2026-03-24	Yu, Yong	Officer	SVP, Clinical Development	Direct	Sale	906	2.42	$2,192.52	144,938	4
2026-03-02	Thomas, John	Director	-	Direct	Sale	10,000	2.90	$29,000.00	482,784	4
2025-12-05	Smalling, Ralph	Officer	Head of Regulatory	Direct	Sale	165	4.69	$773.85	68,658	4
2025-12-01	Thomas, John	Director	-	Direct	Sale	10,000	5.00	$50,000.00	492,784	4
2025-11-17	Yu, Yong	Officer	SVP, Clinical Development	Direct	Sale	973	5.37	$5,225.01	145,844	4
2025-11-17	Zindrick, Thomas	Officer	President and CEO	Direct	Sale	4,509	5.37	$24,213.33	538,431	4
2025-11-17	Cappello, Joseph	Officer	Chief Technical Officer	Direct	Sale	973	5.37	$5,225.01	156,060	4
2025-05-12	Smalling, Ralph	Officer	Head of Regulatory	Direct	Sale	1,259	2.92	$3,676.28	34,760	4
2025-05-12	Yu, Yong	Officer	VP, Clinical Trial Operations	Direct	Sale	5,579	2.92	$16,290.68	47,640	4
2025-05-12	Cappello, Joseph	Officer	VP, Pharmaceutical Development	Direct	Sale	4,737	2.92	$13,832.04	52,266	4
2025-05-12	Zindrick, Thomas	Director,Officer	President and CEO	Direct	Sale	10,764	2.92	$31,430.88	191,447	4
2025-05-12	Ryder, Sean	Officer	General Counsel	Direct	Sale	4,475	2.92	$13,067.00	47,621	4
2024-12-30	Tyree, James L	Director	-	Direct	Sale	3,460	2.46	$8,511.60	45,791	4
2024-12-16	Cappello, Joseph	Officer	VP, Pharmaceutical Development	Direct	Sale	6,300	2.34	$14,742.00	14,653	4
2024-12-16	Zak, Lourie S.	Officer	Chief Financial Officer	Direct	Sale	2,103	2.34	$4,921.02	40,802	4
2024-12-16	Zindrick, Thomas	Director,Officer	President and CEO	Direct	Sale	14,315	2.34	$33,497.10	37,372	4
2024-12-16	Smalling, Ralph	Officer	Head of Regulatory	Direct	Sale	2,510	2.34	$5,873.40	16,322	4
2024-09-13	Szalay, Aladar	TenPercentOwner	-	Indirect	Sale	33,080	2.57	$85,015.60	599,821	4
2024-09-11	Szalay, Aladar	TenPercentOwner	-	Indirect	Sale	31,376	2.62	$82,205.12	664,678	4
2024-09-11	Tyree, James L	Director	-	Direct	Sale	1,730	2.60	$4,498.00	47,521	4
2024-09-03	Szalay, Aladar	TenPercentOwner	-	Indirect	Sale	42,818	2.09	$89,489.62	739,821	4
2024-08-30	Szalay, Aladar	TenPercentOwner	-	Indirect	Sale	142,589	2.17	$309,418.13	782,639	4
2024-08-27	Szalay, Aladar	TenPercentOwner	-	Indirect	Sale	51,630	2.11	$108,939.30	1,048,191	4
2024-06-24	Ryder, Sean	Officer	General Counsel	Direct	Sale	5,496	2.12	$11,651.52	19,388	4
2024-06-24	Yu, Yong	Officer	VP, Clinical Trial Operations	Direct	Sale	6,849	2.12	$14,519.88	10,869	4
2024-06-24	Jewett, Caroline	Officer	Head of Quality	Direct	Sale	4,961	2.12	$10,517.32	16,174	4
2024-05-29	Smalling, Ralph	Officer	Head of Regulatory	Direct	Purchase	1,250	-	-	13,315	4
2024-05-29	Tyree, James L	Director	-	Direct	Purchase	6,250	-	-	9,710	4
2024-05-29	Zindrick, Thomas	Director,Officer	President and CEO	Indirect	Purchase	200,000	-	-	200,000	4
2024-05-29	Mirabelli, Mary	Director	-	Direct	Purchase	8,000	-	-	12,460	4
2024-05-29	Zak, Lourie S.	Officer	Chief Financial Officer	Direct	Purchase	31,250	-	-	31,250	4
2024-05-29	Yu, Yong	Officer	VP, Clinical Trial Operations	Direct	Purchase	2,500	-	-	2,500	4
2024-05-29	Thomas, John	Director	-	Direct	Purchase	2,500	-	-	465,960	4
2024-05-29	Smither, John W	Director	-	Direct	Purchase	6,250	-	-	13,170	4
2024-05-29	Ryder, Sean	Officer	General Counsel	Direct	Purchase	10,000	-	-	10,572	4
2024-05-15	Szalay, Aladar	TenPercentOwner	-	Indirect	Sale	17,094	3.66	$62,564.04	1,139,821	4
2024-05-08	Szalay, Aladar	TenPercentOwner	-	Indirect	Sale	13,919	3.82	$53,170.58	1,175,787	4
2024-05-01	Szalay, Aladar	TenPercentOwner	-	Indirect	Sale	33,061	3.30	$109,101.30	1,195,731	4
2024-04-24	Szalay, Aladar	TenPercentOwner	-	Indirect	Sale	8,064	3.50	$28,224.00	1,255,730	4
2024-04-17	Szalay, Aladar	TenPercentOwner	-	Indirect	Sale	22,737	3.71	$84,354.27	1,300,125	4
2023-12-15	Yu, Yong	Officer	VP, Clinical Trial Operations	Direct	Sale	32,535	13.56	$441,174.60	0	4
2023-12-13	Thomas, John	Director	-	Direct	Sale	9,000	13.58	$122,220.00	463,460	4
2023-12-13	Tyree, James L	Director	-	Direct	Sale	9,000	13.32	$119,880.00	3,460	4
2023-12-07	Yu, Yong	Officer	VP, Clinical Trial Operations	Direct	Sale	36,800	11.85	$436,080.00	32,535	4
2023-11-21	Yu, Yong	Officer	VP, Clinical Trial Operations	Direct	Sale	18,665	10.26	$191,502.90	69,335	4
2023-11-20	Yu, Yong	Officer	VP, Clinical Trial Operations	Direct	Sale	14,594	11.26	$164,328.44	88,000	4
2023-10-25	Szalay, Aladar	TenPercentOwner	-	Indirect	Sale	5,704	19.40	$110,657.60	1,371,545	4
2023-10-24	Yu, Yong	Officer	VP, Clinical Trial Operations	Direct	Sale	5,200	19.11	$99,372.00	106,135	4
2023-10-23	Szalay, Aladar	TenPercentOwner	-	Indirect	Sale	49,987	19.97	$998,240.39	1,377,249	4
2023-10-16	Thomas, John	Director	-	Direct	Sale	3,333	20.90	$69,659.70	472,460	4
2023-10-10	Yu, Yong	Officer	VP, Clinical Trial Operations	Direct	Sale	5,200	22.42	$116,584.00	106,135	4
2023-10-05	Szalay, Aladar	TenPercentOwner	-	Indirect	Sale	14,251	25.18	$358,840.18	1,427,236	4
2023-10-03	Szalay, Aladar	TenPercentOwner	-	Indirect	Sale	75,690	25.49	$1,929,338.10	1,441,487	4
2023-09-28	Szalay, Aladar	TenPercentOwner	-	Indirect	Sale	2,289	24.12	$55,210.68	1,517,177	4
2023-09-26	Szalay, Aladar	TenPercentOwner	-	Indirect	Sale	29,805	23.67	$705,484.35	1,530,723	4
2023-09-26	Yu, Yong	Officer	VP, Clinical Trial Operations	Direct	Sale	5,200	23.50	$122,200.00	106,135	4
2023-09-22	Szalay, Aladar	TenPercentOwner	-	Indirect	Sale	9,042	27.32	$247,027.44	1,572,986	4
2023-09-20	Ryder, Sean	Officer	General Counsel	Direct	Sale	10,000	30.00	$300,000.00	572	4
2023-09-20	Yu, Yong	Officer	VP, Clinical Trial Operations	Direct	Sale	6,000	27.96	$167,760.00	106,135	4
2023-09-19	Szalay, Aladar	TenPercentOwner	-	Direct	Sale	32,167	26.68	$858,215.56	0	4
2023-09-18	Thomas, John	Director	-	Direct	Sale	3,334	24.99	$83,316.66	475,793	4
2023-09-15	Yu, Yong	Officer	VP, Clinical Trial Operations	Direct	Sale	10,400	21.92	$227,968.00	106,135	4
2023-09-14	Szalay, Aladar	TenPercentOwner	-	Indirect	Sale	25,276	22.04	$557,083.04	35,292	4
2023-09-13	Yu, Yong	Officer	VP, Clinical Trial Operations	Direct	Sale	29,800	21.14	$629,972.00	106,135	4
2023-09-13	Smither, John W	Director	-	Direct	Sale	900	20.78	$18,702.00	6,920	4
2023-09-12	Szalay, Aladar	TenPercentOwner	-	Indirect	Sale	20,265	22.13	$448,464.45	79,600	4
2023-09-08	Szalay, Aladar	TenPercentOwner	-	Indirect	Sale	24,831	23.49	$583,280.19	132,216	4
2023-08-30	Yu, Yong	Officer	VP, Clinical Trial Operations	Direct	Sale	19,800	24.70	$489,060.00	135,935	4
2023-08-18	Yu, Yong	Officer	VP, Clinical Trial Operations	Direct	Sale	3,265	23.73	$77,478.45	155,735	4
2023-08-18	Ryder, Sean	Officer	General Counsel	Direct	Sale	328	23.73	$7,783.44	572	4
2023-08-18	Samuelson, Doug	Officer	Chief Financial Officer	Direct	Sale	1,297	23.73	$30,777.81	2,303	4
2023-08-18	Cappello, Joseph	Officer	VP, Pharmaceutical Development	Direct	Sale	3,265	23.73	$77,478.45	5,735	4
2023-08-18	Smalling, Ralph	Officer	Head of Regulatory	Direct	Sale	935	23.73	$22,187.55	2,065	4
2023-08-18	Zindrick, Thomas	Director,Officer	President and CEO	Direct	Sale	8,349	23.73	$198,121.77	14,651	4
2023-08-18	Jewett, Caroline	Officer	Head of Quality	Direct	Sale	515	23.73	$12,220.95	1,135	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

20.99%

Inst. Shares: 9,268,229

Shares Outstanding: 44,150,958

2025-12-31

24.48%

Inst. Shares: 9,102,602

Shares Outstanding: 37,176,527

2025-09-30

19.58%

Inst. Shares: 7,421,090

Shares Outstanding: 37,893,314

2025-06-30

19.14%

Inst. Shares: 7,264,585

Shares Outstanding: 37,946,330

2025-03-31

20.68%

Inst. Shares: 7,220,986

Shares Outstanding: 34,926,075

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	9,268,229	44,150,958	20.99%
2025-12-31	9,102,602	37,176,527	24.48%
2025-09-30	7,421,090	37,893,314	19.58%
2025-06-30	7,264,585	37,946,330	19.14%
2025-03-31	7,220,986	34,926,075	20.68%
2024-12-31	4,840,333	31,450,727	15.39%
2024-09-30	5,214,692	34,532,355	15.10%
2024-06-30	7,043,517	29,689,344	23.72%
2024-03-31	5,895,980	26,849,737	21.96%
2023-12-31	5,709,548	24,429,278	23.37%
2023-09-30	4,204,024	26,210,068	16.04%
2023-06-30	488,441	25,068,334	1.95%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

GENELUX Corp (GNLX) — SEC Financial Statements & Analysis

GENELUX Corp (GNLX) is a pharmaceutical preparations company, incorporated in DE. GENELUX Corp trades on Nasdaq as: GNLX. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), GENELUX Corp reported a -100.00% year-over-year revenue growth, a Debt-to-Equity ratio of 0.63x, a Price-to-Sales (P/S) ratio of 9277.96x (TTM), a Price-to-Book (P/B) ratio of 8.40x (TTM), at a market cap of $135.33M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -100.00%
Debt To Equity: 0.63x
P/S TTM: 9277.96x
P/B TTM: 8.40x
Market Cap: $135.33M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is GENELUX Corp in?

GENELUX Corp (GNLX) operates in the Pharmaceutical Preparations industry.

What is GNLX's market cap?

GENELUX Corp (GNLX) has a market capitalization of $135.33M as of 2026-06-30.

What exchange does GNLX trade on?

GENELUX Corp (GNLX) trades on the Nasdaq.

Where is GENELUX Corp incorporated?

GENELUX Corp is incorporated in DE.

GENELUX Corp

Financial Statements

Custom Table

Interactive Financial Visualizations

Earnings Market Reaction

Performance and Valuation Metrics

Insider Transactions

Institutional Ownership

GENELUX Corp (GNLX) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Pharmaceutical Preparations

Wall Street's data.
Main Street's price.

GENELUX Corp (GNLX) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Pharmaceutical Preparations

Wall Street's data.Main Street's price.

Wall Street's data.
Main Street's price.